Event-Driven Stocks

Dermata Therapeutics, Inc.

DRMANasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 1 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue——————
Operating income−$7.8M−$12.5M−$8.0M−$9.7M−$7.9M−$3.2M
Net income−$7.6M−$12.3M−$7.8M−$9.6M−$7.9M−$3.2M
Total assets$7.9M$3.5M$8.0M$6.9M$11.6M$605,453
Total liabilities$1.6M$2.0M$1.6M$922,634$1.5M$3.8M
Equity$6.2M$1.6M$6.4M$6.0M$10.1M−$3.2M
EPS (diluted)$-8.16$-8.03$-39.99$-13.92$-2.43$-1.69
Shares out.5.4M6.7M12.3M8.3M8.3M—

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
−121.5%
Return on assets
−96.1%
Return on capital (ROCE)
—
Liabilities / assets
20.9%
Debt / equity
0.26×
Book value / share
$1.15
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Accruals / assets
2.5%clean
Piotroski F-Score
3/6weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
58
/ 100
Profitability 0Growth n/aCatalyst 100Earnings quality 33Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 1 warning● 2 good
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
1 acquisitions0 disposals1 open-market buy(s)net +1,000 shares · last 1
InsiderDateTypeSharesPrice
Bedoya-Toro Munera Maria EOfficer — SVP, Regulatory AffairsFeb 17, 2026Buy1,000$1.27

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 2026114,5882.2-24.2%
Apr 30, 2026151,1041.8-24.6%
Apr 15, 2026200,3442.3-24.1%
Mar 31, 2026264,0371.0+500.9%
Mar 13, 202643,9391.0-61.0%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.